Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.

Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, Morlock L, Lotan Y, Raj GV, Sagalowsky A, Margulis V, Cadeddu JA, Ross MT, Bentley DR, Kabbani W, Xie XJ, Kapur P, Williams NS, Brugarolas J.

Sci Transl Med. 2012 Jun 6;4(137):137ra75. doi: 10.1126/scitranslmed.3003643.

PMID:
22674553
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.

Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B.

Clin Cancer Res. 2013 Mar 1;19(5):1257-68. doi: 10.1158/1078-0432.CCR-12-2885. Epub 2013 Jan 21.

PMID:
23339124
[PubMed - indexed for MEDLINE]
Free Article
3.

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue.

Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, Ishkin A, Nikolsky Y, Resau JH, Sigler R, Nickoloff BJ, Webb CP.

J Transl Med. 2012 Jun 18;10:125. doi: 10.1186/1479-5876-10-125.

PMID:
22709571
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.

Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8.

PMID:
23658459
[PubMed - indexed for MEDLINE]
Free Article
5.

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST.

Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22.

PMID:
20028765
[PubMed - indexed for MEDLINE]
Free Article
6.

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM.

Neoplasia. 2009 Sep;11(9):910-20.

PMID:
19724685
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.

Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM.

Urol Oncol. 2014 Jan;32(1):43.e23-30. doi: 10.1016/j.urolonc.2013.05.008. Epub 2013 Aug 2.

PMID:
23911681
[PubMed - in process]
8.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.

Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25.

PMID:
20501804
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.

Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.

Cancer Res. 1997 Nov 1;57(21):4803-10.

PMID:
9354442
[PubMed - indexed for MEDLINE]
Free Article
10.

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.

Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B.

Clin Genitourin Cancer. 2013 Jun;11(2):128-33. doi: 10.1016/j.clgc.2012.12.001. Epub 2013 Jan 17.

PMID:
23332872
[PubMed - indexed for MEDLINE]
11.

Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing.

Pavía-Jiménez A, Tcheuyap VT, Brugarolas J.

Nat Protoc. 2014 Aug;9(8):1848-59. doi: 10.1038/nprot.2014.108. Epub 2014 Jul 10.

PMID:
25010905
[PubMed - in process]
12.

Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.

Yamamoto K, Mizutani Y, Nakanishi H, Fujiwara J, Ishida H, Toiyama D, Abe K, Hayashi I, Okada K, Kawauchi A, Mizuno M, Yoshida J, Miki T.

Int J Oncol. 2008 Sep;33(3):565-71.

PMID:
18695887
[PubMed - indexed for MEDLINE]
13.

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.

Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia C.

Br J Cancer. 2013 Jul 23;109(2):332-41. doi: 10.1038/bjc.2013.341. Epub 2013 Jun 27.

PMID:
23807171
[PubMed - indexed for MEDLINE]
14.

Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model.

Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, Kucuk O, Sarkar FH.

BMC Cancer. 2007 Jan 9;7:4.

PMID:
17212824
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.

Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP.

J Transl Med. 2012 Dec 10;10:245. doi: 10.1186/1479-5876-10-245.

PMID:
23228017
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM.

Mol Cancer Ther. 2009 Jun;8(6):1448-59. doi: 10.1158/1535-7163.MCT-09-0101. Epub 2009 Jun 9.

PMID:
19509240
[PubMed - indexed for MEDLINE]
Free Article
17.

Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.

Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM.

J Hepatol. 2012 Mar;56(3):595-601. doi: 10.1016/j.jhep.2011.09.017. Epub 2011 Oct 23.

PMID:
22027573
[PubMed - indexed for MEDLINE]
18.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
[PubMed - indexed for MEDLINE]
19.

Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.

Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H.

Int J Oncol. 2012 Aug;41(2):712-20. doi: 10.3892/ijo.2012.1494. Epub 2012 May 23.

PMID:
22641227
[PubMed - indexed for MEDLINE]
20.

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA, Tsao MS.

Clin Cancer Res. 2011 Jan 1;17(1):134-41. doi: 10.1158/1078-0432.CCR-10-2224. Epub 2010 Nov 16.

PMID:
21081655
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk